个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study

| 认领 | 导出 | |

文献详情

资源类型：
Pubmed体系：
作者：
Chen Chunji[1] * ; Tian Ziqiang[2] * ; Lin Jiangbo[3,4,5] * ; Leng Xuefeng[6] * ; Shen Jianfei[7,8] * ; Zhao Jinbo[9] ; Lv Huilai[2] ; Wang Changchun[10] ; Mei Xinyu[11,12] ; Han Yongtao[6] ; Wang Qifeng[13] ; Lv Jiahua[13] ; Chen Hainan[13] ; Yan Xiaolong[9] ; Liu Zhichao[1] ; Zhang Zhengyang[3,4,5] ; Zhong Qihong[3,4,5] ; Jiang Youhua[10] ; Xu Liwei[10] ; Li Xiaoyang[12,14] ; Qian Dong[12,14] ; Ma Dehua[7,15] ; Ye Minhua[7] ; Wang Chunguo[7] ; Wang Zimin[7] ; Li Zhigang[1] ; Guo Xufeng[1] ;
机构： [1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China. [2]Department of Thoracic Surgery, The Fourth Hospital of Hebei Medical University, Shijiazhuang, China. [3]Clinical Research Center for Thoracic Tumors of Fujian Province, Fuzhou, China. [4]Department of Thoracic Surgery, Fujian Medical University Union Hospital, Fuzhou, China. [5]Key Laboratory of Cardio-Thoracic Surgery (Fujian Medical University), Fujian Province University, Fuzhou, China. [6]Department of Thoracic Surgery, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, China. [7]Department of Thoracic Surgery, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University, Linhai, China. [8]Key Laboratory of Minimally Invasive Techniques & Rapid Rehabilitation of Digestive System Tumor of Zhejiang Province, Linhai, China. [9]Department of Thoracic Surgery, Tangdu Hospital, Air Force Medical University, Xi'an, China. [10]Department of Thoracic Surgery, Zhejiang Cancer Hospital, Hangzhou, China. [11]Department of Thoracic Surgery, The First Affiliated Hospital of USTC, University of Science and Technology of China (USTC), Hefei, China. [12]Division of Life Sciences and Medicine, University of Science and Technology of China (USTC), Hefei, China. [13]Department of Radiation Oncology, Sichuan Cancer Hospital and Research Institute, School of Medicine, University of Electronic Science and Technology of China (UESTC), Chengdu, China. [14]Department of Radiation Oncology, The First Affiliated Hospital of USTC, University of Science and Technology of China (USTC), Hefei, China. [15]EnzeHospital, Taizhou Enze Medical Center (Group), Taizhou, China.
出处：
DOI： 10.1097/JS9.0000000000003546
ISSN：

关键词： Esophageal Squamous Cell Carcinoma Adjuvant Immunotherapy Neoadjuvant Chemoimmunotherapy Multicenter Real-World Study

摘要：
Although adjuvant immunotherapy demonstrated an improvement in disease-free survival (DFS) within the chemoradiotherapy cohort of the CheckMate 577 trial, its efficacy and role following NCIT remain to be elucidated. This large-sample, multicenter, real-world study aims to assess survival benefits of adjuvant immunotherapy in esophageal squamous cell carcinoma (ESCC) patients treated with neoadjuvant chemoimmunotherapy (NCIT) followed by R0 resection.This multicenter retrospective study (8 centers, Jan 2019-Mar 2023) included 724 ESCC patients undergoing NCIT and R0 resection. Propensity score matching (PSM) balanced 262 patients per group: NCIT + Surgery (NCIT + S) vs. NCIT + Surgery + adjuvant immunotherapy (NCIT + S + ICI). Primary endpoints were 2-year overall survival (OS) and DFS; secondary endpoints included recurrence patterns.Median follow-up: 31.2 months (IQR 24.0-39.9). Post-PSM analysis showed no significant OS benefit (2-year OS: 80.0% vs. 84.5%, HR = 1.15, 95% CI:0.78-1.70, p = 0.12) or DFS improvement (77.7% vs. 72.6%, HR = 0.97, 95% CI:0.69-1.37, p = 0.69) for NCIT + S vs. NCIT + S + ICI. Adjuvant immunotherapy was not independently protective for OS (HR = 0.87, p = 0.48) or DFS (HR = 1.03, p = 0.87). However, subgroup analyses revealed OS benefits in Non-MPR patients (63.9% vs. 81.7%, HR = 1.78, 95% CI:1.05-3.03, p = 0.035) and Non-pCR patients (74.9% vs. 84.3%, HR = 1.39, 95% CI:1.19-2.10, p = 0.031). Recurrence rates did not differ (local:15.3% vs.20.2%, p = 0.50; distant:16.8% vs.21.6%, p = 0.17).Adjuvant immunotherapy provided no survival benefit in the overall NCIT-treated ESCC cohort but improved OS in patients with residual tumor (Non-MPR/Non-pCR). Further studies are warranted to refine patient selection for adjuvant immunotherapy in this setting.Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc.

语种：
外文
PubmedID：
中科院(CAS)分区：
出版当年[2025]版：
大类 | 2 区 医学
小类 | 2 区 外科
最新[2025]版：
大类 | 2 区 医学
小类 | 2 区 外科
第一作者：
第一作者机构： [1]Department of Thoracic Surgery, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
共同第一作者：
通讯作者：
推荐引用方式(GB/T 7714)：
Chen Chunji,Tian Ziqiang,Lin Jiangbo,et al.Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study[J].International Journal Of Surgery (London, England).2025,doi:10.1097/JS9.0000000000003546.
APA：
Chen Chunji,Tian Ziqiang,Lin Jiangbo,Leng Xuefeng,Shen Jianfei...&Guo Xufeng.(2025).Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study.International Journal Of Surgery (London, England),,
MLA：
Chen Chunji,et al."Adjuvant immunotherapy for esophageal squamous cell carcinoma after neoadjuvant chemoimmunotherapy: a multicenter real-world study".International Journal Of Surgery (London, England) .(2025)

相关文献

[1]Neoadjuvant Chemoradiotherapy vs Chemoimmunotherapy for Esophageal Squamous Cell Carcinoma [2]Effectiveness and safety of first-line pembrolizumab plus chemotherapy in patients with advanced/recurrent or metastatic esophageal squamous cell carcinoma in China: a real-world multicenter study [3]Impact of first-line chemoimmunotherapy with or without radiotherapy on the prognosis of patients with locally advanced or metastatic esophageal squamous cell carcinoma: a multicenter, real-world, retrospective cohort study from China (NCT06478355) [4]Tislelizumab Plus Chemotherapy Sequential Neoadjuvant Therapy for Non-cCR Patients After Neoadjuvant Chemoradiotherapy in Locally Advanced Esophageal Squamous Cell Carcinoma (ETNT): An Exploratory Study [5]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [6]Comprehensive evaluation of a multicenter real-world study: Neoadjuvant immunochemotherapy in locally advanced gastric cancer [7]Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China [8]Identifying a confused cell identity for esophageal squamous cell carcinoma. [9]Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC [10]Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real-world study

资源点击量：65780 今日访问量：0 总访问量：5151 更新日期：2025-12-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号